Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magnesium Sulphate for Neuroprotection in Preterm Deliveries
NCT05674565Phase 3Unknown
- Sponsor
- Zagazig University
- Start
- Jan 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of magnesium sulfate in cerebral palsy (CP) and neonatal death (3 arms), sponsored by Zagazig University. Primary endpoints: Neonatal Neurological insult at 18 months, Maternal toxicity and 1 more. Status: unknown.
02
Drugs
magnesium sulfate
03
Conditions
cerebral palsy (CP)neonatal death
Beyond the preview
Go deeper on NCT05674565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05674565.